Solodex-JR 0.45-5 Injection can be administered intramuscularly (IM) or intravenously (IV). For IV administration, it can be given slowly directly or as an infusion after dilution. The rate of injection should be slow to avoid adverse effects. It should not be injected subcutaneously.

Dexamethasone Sodium Phosphate acts by binding to glucocorticoid receptors in the cytoplasm, forming a steroid-receptor complex. This complex then translocates to the nucleus, where it binds to specific DNA sequences (glucocorticoid response elements), altering gene expression. This leads to the synthesis of anti-inflammatory proteins (e.g., lipocortin) and inhibition of pro-inflammatory mediators (e.g., prostaglandins, leukotrienes), thereby reducing inflammation and immune response.

• •Systemic fungal infections (unless anti-fungal therapy is also used)
• •Hypersensitivity to dexamethasone or any component of the formulation
• •Administration of live or live-attenuated vaccines in patients receiving immunosuppressive doses

Store below 25°C (77°F). Protect from light. Do not freeze. Keep out of reach of children.

Acute overdose with corticosteroids is rare. Symptoms may include fluid retention, hypertension, hyperglycemia, and potassium loss. Treatment is supportive and symptomatic; no specific antidote exists. Gradually reduce dosage.

Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Dexamethasone is excreted in breast milk and may cause adverse effects in infants. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.